Plain-English translation of NCT06225804 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called in people with non-small cell lung cancer, specifically those whose cancer has an EGFR exon 20 insertion mutation. The trial will first determine the safest dose by starting at a low dose and gradually increasing it in different patient groups. Then, a larger group of patients will take the medication at the dose that was found to be safe, to see if it can help shrink or control their tumors.
Currently, treatment options are limited for people whose lung cancer has this specific genetic mutation. This medication is being developed to directly target and block the harmful effects of this mutation, potentially offering patients a new way to fight their cancer.
You likely qualify if…
You likely don't qualify if…
During the first part of the trial, you would visit the clinic regularly to receive the medication by mouth (as a capsule or tablet) and have your safety monitored closely through blood tests and scans. The study uses a careful approach that starts with the lowest dose and increases it gradually across different patient groups until the safest effective dose is found. Once that dose is determined, additional patients will receive the medication at that dose in 28-day treatment cycles, with regular clinic visits to check if the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States
China